BGI
B Group Inc Portfolio holdings
AUM
$116M
This Quarter Return
+9.38%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$115M
AUM Growth
+$115M
(+9%)
Cap. Flow
+$2.62M
Cap. Flow
% of AUM
2.28%
Top 10 Holdings %
Top 10 Hldgs %
93.62%
Holding
19
New
2
Increased
11
Reduced
2
Closed
–
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
$1.69M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$1.44M |
| 3 |
Assembly Biosciences
ASMB
|
$1.43M |
| 4 |
BioNTech
BNTX
|
$1.05M |
| 5 |
Praxis Precision Medicines
PRAX
|
$720K |
Top Sells
| 1 |
Insmed
INSM
|
$6.68M |
| 2 |
Akero Therapeutics
AKRO
|
$708K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$4.12B
| $46M | 39.39% | 2,317,542 +30,000 | +1% | +$595K |
|
|
2
Insmed
INSM
$28.8B
| $20M | 17.16% | 262,500 -87,500 | -25% | -$6.68M |
|
3
Zai Lab
ZLAB
$3.68B
| $14.5M | 12.38% | 400,000 | – | – |
|
|
4
Akero Therapeutics
AKRO
$3.74B
| $9.82M | 8.41% | 242,500 -17,500 | -7% | -$708K |
|
|
5
Iovance Biotherapeutics
IOVA
$807M
| $5M | 4.28% | 1,500,000 +508,000 | +51% | +$1.69M |
|
|
CLLS
6
Cellectis
CLLS
$258M
| $4.04M | 3.46% | 3,256,501 +175,000 | +6% | +$217K |
|
7
Aura Biosciences
AURA
$389M
| $2.77M | 2.37% | 472,576 | – | – |
|
8
Sight Sciences
SGHT
$213M
| $2M | 1.71% | 833,600 +204,230 | +32% | +$490K |
|
|
9
Assembly Biosciences
ASMB
$190M
| $1.91M | 1.64% | 200,000 +149,349 | +295% | +$1.43M |
|
10
Taysha Gene Therapies
TSHA
$797M
| $1.75M | 1.5% | 1,255,556 +290,000 | +30% | +$403K |
|
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.72M | 1.47% | 47,500 +39,904 | +525% | +$1.44M |
|
|
12
BioNTech
BNTX
$24B
| $1.37M | 1.17% | 15,000 +11,500 | +329% | +$1.05M |
|
13
Spyre Therapeutics
SYRE
$996M
| $1.13M | 0.97% | 70,000 +20,000 | +40% | +$323K |
|
14
Apogee Therapeutics
APGE
$2.17B
| $1.12M | 0.96% | 30,000 +15,000 | +100% | +$560K |
|
|
15
Praxis Precision Medicines
PRAX
$958M
| $720K | 0.62% | +19,000 | New | +$720K |
|
16
89bio
ETNB
$1.34B
| $695K | 0.6% | +95,623 | New | +$695K |
|
|
ORKA
17
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $597K | 0.51% | 58,215 +38,215 | +191% | +$392K |
|
18
Corvus Pharmaceuticals
CRVS
$428M
| – | – | 0 | – | – |
|
19
Invesco QQQ Trust
QQQ
$364B
| – | – | 0 | – | – |
|